Karen Akinsanya, Executive Vice President, Chief Biomedical Scientist, Head of Discovery R&D, joined Schrödinger in 2018. Karen leads the Discovery R&D group with responsibility for preclinical drug discovery and translational research. She has more than 25 years of experience in academia, pharmaceutical R&D, partnerships, and licensing.
Karen joined Merck Research Labs in 2005 and held positions of increasing responsibility in clinical pharmacology as a development team leader working on first-in-human studies through late-stage label studies before joining Discovery Preclinical & Early Development as a therapeutic area lead and then a search and evaluation lead in business development.
She received her Ph.D. from the Royal Postgraduate Medical School at Imperial College in London, in endocrine physiology. After post-doctoral training at Imperial and the Ludwig Institute for Cancer Research (UCL), Karen joined Ferring Pharmaceuticals in R&D working across sites in the UK and US. At Ferring, she led the discovery of a family of dipeptidyl peptidases related to DPPIV and pre-clinical characterization of FDA-approved FIRMAGON® for prostate cancer.